No. rejected | Reason | Total |
Total identified | 508 | |
171 | Not relevant | 337 |
72 | Reviews | 265 |
29 | Not American College of Rheumatology criteria | 236 |
20 | Not clinical trials | 216 |
19 | Abstracts | 197 |
8 | No pain or function assessments | 189 |
5 | Follow-up data only | 184 |
4 | Fibromyalgia syndrome combined for analysis | 180 |
Eligible clinical trials | ||
19 | Data recorded, but not given | 161 |
4 | Non-English language: translations reveal to be ineligible | 157 |
12 | Non-English language: translations not available | 145 |
+1 | Identified from bibliographies | 146 |
The 146 eligible clinical trials included 59 pharmacological and 87 non-pharmacological (including multidisciplinary). Studies were further subdivided into treatment interventions and the highest quality studies from each intervention were selected to be the basis for recommendations (table 2).